NCT05176223CompletedPhase 2
68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer
Optimizing Outcomes of Patients With Advanced HCC Undergoing Immunotherapy Through Novel 68Ga PSMA PET Imaging
Source: ClinicalTrials.gov · Last updated 29 Sept 2026
Brief summary (registry, in English)
This phase II trial tests whether 68-Gallium prostate specific membrane antigen (68Ga-PSMA) positron emission tomography (PET) imaging can improve the diagnosis and management of liver cancer that has spread to other parts of the body (advanced). PSMA is a protein that appears in large amounts on the surface of liver cancer cells. The radioactive chemical compound (68Ga-PSMA) has been designed to circulate through the body and attach itself to the PSMA protein on liver cancer cells. A PET scan is then used to detect the location of the tumor cells. 68Ga-PSMA PET may improve upon the diagnosis and management of liver cancer.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 26 (actual)
- First submitted
- 22 Nov 2021
- Start date
- 30 Jan 2022
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Mayo Clinic
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT05176223
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 26
- From 30 Jan 2022 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Pregnant and/or breast-feeding patients. A negative pregnancy test within 48 hours of the PET scan
- Patients with higher than the weight/size limitations of PET/CT scanner
Who the study is looking for
- Patient with pathologically confirmed HCC not amenable to curative resection, transplantation or ablative therapies
- Have radiographically measurable disease by RECIST
- Eligible for atezolizumab/bevacizumab front line therapy
- Male or female with age greater than 18 years, with the capacity and willingness to provide written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic in Rochester Coordinator of this site? Confirm its status | Rochester | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.